Skip to main content
Clinical Trials/JPRN-UMIN000047024
JPRN-UMIN000047024
Completed
未知

A long term clinical study for safety evaluation of containing plant-extracts foods. (SME-2021-07) - A long term clinical study for safety evaluation of containing plant-extracts foods.

Suntory Beverage & Food Limited0 sites48 target enrollmentMarch 4, 2022
Conditionsot applicable

Overview

Phase
未知
Intervention
Not specified
Conditions
ot applicable
Sponsor
Suntory Beverage & Food Limited
Enrollment
48
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 4, 2022
End Date
July 9, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Suntory Beverage & Food Limited

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\) Those with systolic blood pressure less than 90 mmHg at the start of ingestion. (2\) Women who are/might be pregnant or lactating during the study. (3\) Those who have taken \>\=200 mL whole blood or blood donation within 4 weeks before the start of the intake. (4\) Men who have taken \=\>400 mL whole blood within 12 weeks before the start of intake. (5\) Women who have taken \=\>400 mL whole blood within 16 weeks before the start of intake. (6\) Men who have taken \=\>1,200 mL whole blood total (including the sampling of this study) within 12 months before the start of intake. (7\) Women who have taken \=\>800 mL whole blood total (including the sampling of this study) within 12 months before the start of intake. (8\) Those who are participating in other study or planning to participate or participated within the past 4 weeks. (9\) Those who meet any of the following: a) suffering from heart, liver, or kidney disease (including complications of other diseases) b) having a history of cardiovascular disease c) diabetes d) allergic to food e) having a history of cancer or tuberculosis f) positive or false\-positive by infectious disease test (10\) Those who are receiving any treatment at the time of screening. (11\) Those who regularly use pharmaceuticals (including quasi\-drugs), foods for specified health use, foods with functional claims or health foods. (12\) Those who smoke an average of 21 or more cigarettes in a day. (13\) Those who drink an average of more than 60 g of pure alcohol in a day. (14\) Those who have an extremely irregular eating habit. (15\) Shift workers or late\-night workers. (16\) Others who are judged inappropriate for participant by the investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Clinical study to investigate the long-term safety and efficacy of human cell line recombinant Factor VIII (human-cl rhFVIII) in previously treated patients with severe haemophilia ASevere haemophilia AHaematological DisordersHereditary factor VIII deficiency
ISRCTN90038418Octapharma AG (Switzerland)22
Active, not recruiting
Phase 1
A long-term study to monitor the health status of people with cystic fibrosis who took part in a previous study with BI 3720931 (LenticlairTM-ON)Cystic fibrosisMedDRA version: 20.0Level: PTClassification code: 10011763Term: Cystic fibrosis lung Class: 100000004850Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
CTIS2023-504909-37-00Boehringer Ingelheim International GmbH27
Active, not recruiting
Not Applicable
Clinical study for the assessment of safety and efficacy of Bezafibrate as a drug therapy for patients suffering from an inborn muscular dysfunction characterized by intramuscular lack of energy supplymitochondrial disorderTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2012-002692-34-ATniv.-Klinik für Kinder- und Jugendheilkunde16
Active, not recruiting
Phase 1
A long-term monitoring study of patients suffering from a malignant neoplasm of the central nervous system previously treated with hematopoietic stem cellsGlioblastoma multiforme (GBM)MedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2021-000700-38-ITGENENTA SCIENCE SR5
Active, not recruiting
Phase 2
Study to evaluate the safety and efficacy of the Versius surgical system in robot-assisted cholecystectomy (a surgical procedure to remove your gallbladder)Robot assisted cholecystectomySurgery
ISRCTN17254664CMR Surgical (United Kingdom)30